Thesis update on Humacyte
Very good summary of the situation I found on Twitter, updated as of June 2026
"The framing is deliberately split into three separate questions, since the market is currently pricing them as one: the science, the company, and the stock.
On science: V012 met its primary endpoint in dialysis vascular access — 91 more catheter-free days versus the standard AV fistula (p=0.00070), the strongest data point in the company's history.
On the company: commercial execution remains unproven, gross margin is still deeply negative, and 2026 has brought two dilutive raises, each priced worse than the last, alongside a formal going-concern disclosure.
On the stock: it now sits outside the Russell indexes, with a Nasdaq minimum-bid risk that resurfaced after the latest raise.
Full breakdown below: trauma, dialysis, the sBLA pathway, financials, governance, manufacturing economics, and a full risk map"